Subtyping analysis of tumor immunity revealed that ccRCC patients were mainly clustered in three subtypes, C2 (IFN-γ dominant), C3 (inflammatory) and C4 (lymphocyte depleted) [36], which is highly consistent with our previous suggestion that attenuating the inflammatory response might be able to therapeutically treat the tumor. This evidence concerns the gene IFNG and neoplasm.